The varicella-zoster virus (VZV) Oka vaccine strain (vOka) differs from the parental strain (pOka) at several amino acid positions, but the mutations responsible for the attenuation of vOka have not been clearly defined. The ORF0 of vOka carries some of the mutations. Although we found that the ORF0 of both strains was incorporated into virus particles, the C-terminal region of vOka ORF0 was presented on the virion surface and was N-glycosylated, suggesting that the mutation in vOka ORF0 changes it into a novel envelope glycoprotein. In a mutant virus in which pOka ORF0 was replaced by vOka ORF0, the molecular weight of ORF0 was altered, but the plaque size was not. In addition, a pOka recombinant virus lacking the hydrophobic domain of ORF0 grew equally well as the wild-type virus, indicating that the mutation in ORF0 is not by itself sufficient for the attenuation of the vOka virus.
Introduction
Varicella-zoster virus (VZV) is a member of the human alphaherpesvirus subfamily and causes chickenpox (varicella) and shingles (zoster) (Cohen et al., 2007) . Varicella is highly infectious. In children, it is associated with fever and generalized pruritic vesicular rash. The virus establishes latency in cells of the dorsal root ganglia during the primary infection. Herpes zoster is caused by the reactivation of VZV and is usually observed later in life.
To control VZV infection, a live attenuated vaccine (vOka) was developed from the Oka parental strain (pOka) (Takahashi et al., 1974) . The attenuated vOka was obtained by multiple passages of pOka through human and guinea pig cells. The resulting attenuated strain became the first herpesvirus vaccine licensed for use in humans. Vaccination with vOka is efficient and causes few adverse events. Consequently, it is the only strain to be used worldwide (Arvin, 2001; Chaves et al., 2008) . Although vOka's infectivity is attenuated in the skin zenograft SCID-hu mouse model (Moffat et al., 1998) , it retains the capacity to downregulate the expression of major histocompatibility complex class I (Abendroth et al., 2001) . The delay in the production of infectious vOka at the site of subcutaneous inoculation allows enough time for the induction of adaptive immunity. Despite its widespread use and effectiveness as a vaccine, however, the molecular mechanisms of vOka's attenuation are not well understood,.
A comparison of the pOka and vOka genomic sequences by Gomi et al. (2002) showed 42 mutated sites in vOka, with 20 amino acid substitutions in open reading frames (ORFs). In addition, Kemble et al. (2000) showed another amino acid substitution in ORF0. Therefore, a total of 21 amino acid substitutions are found in the ORFs of vOka. The sequence polymorphisms presented in Gomi et al. (2000) show only 15 of these 21 substitutions because vOka consists of a mixture of closely related viruses. The remaining 6 amino acid substitutions are located in ORF0, ORF6, and ORF62 and may contribute to the vOka attenuation.
The amino acid substitution in ORF0 is particularly interesting. ORF0 is encoded at the start site on the left side of the unique long (UL) region of the VZV genome. It is a positional and sequence homolog of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) UL56. Neither ORF0 nor UL56 has an N-terminal signal sequence, and both possess a transmembrane domain (TMD) at the C-terminus (Koshizuka et al., 2002) . These are features of tail-anchored (TA) proteins (Borgese et al., 2003; High and Abell, 2004; Kutay et al., 1993; Wattenberg and Lithgow, 2001) . The ORF0 protein of vOka possesses an extended C-terminal sequence because of a point mutation in its stop codon (Kemble et al., 2000) . Finally, an ORF0-null VZV mutant, generated by using the bacterial artificial chromosome (BAC) system, shows severely retarded growth both in vitro and in vivo (Zhang et al., 2007) .
In the present study, we investigated the role of ORF0 in VZV attenuation by preparing anti-ORF0 mono-specific antibodies in rabbits and characterizing the ORF0 protein. We found that ORF0 is incorporated into virus particles and that the extended C-terminal domain of Virology 405 (2010) Contents lists available at ScienceDirect Virology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y v i r o vOka ORF0, but not the wild-type ORF0 of pOka, is N-glycosylated and presented on the surface of the virion.
Results

Construction of the ORF0 gene
The ORF0 protein is encoded by the nucleotide (nt) sequence from position 172 to 558 of the pOka genome. The stop codon of pOka ORF0 is at nucleotide (nt) position 559 of the pOka genome. The thymine at nt 559 of the pOka genome is replaced by a cytosine in the vOka genome (Fig. 1A,  arrowhead) , and the resulting protein indicates that the ORF0 gene lies between nt positions 172 and 834 of the vOka genome (Kemble et al., 2000) . The ORF0 gene encodes a spliced mRNA in addition to an unspliced one (Fig. 1) . Because both of the vOka ORF0 gene products are predicted to be translated, both variants were cloned into plasmids and sequenced.
The stop codon of the spliced vOka ORF0 was at nt position 767, and the splice junction was at nt positions 583 to 714. The stop codon of the unspliced ORF0 was at nt position 835. Two single nucleotide polymorphisms have been reported at positions 702 and 762 (Fig. 1A, open arrowheads) of the vOka genome. These are located within the ORF1 gene (Gomi et al., 2002) (Fig. 1A) . In the spliced vOka ORF0, the polymorphism at 702 was spliced out, and the one at nt 762 caused a substitution of valine for alanine, at amino acid position 154 (Fig. 1B,  vertical line) . In the unspliced vOka ORF0, the nt mutations were silent and therefore did not affect the amino acid sequence. Therefore, the ORF0 protein of pOka contains 129 amino acids (aa); the spliced variant of vOka ORF0 contains 155 aa, and the unspliced one contains 221 aa (Fig. 1B) . The molecular weight of each ORF0 protein predicted from the amino acid sequence was 14 kDa in pOka, 17 kDa for the spliced form in vOka, and 23 kDa for the unspliced form in vOka (Table 1) .
Predicted C-terminal transmembrane domain and classification of ORF0
The ORF0 protein contains a C-terminal hydrophobic domain from amino acids 100 to 120 (Figs. 1B and C). We generated a Kyte and Doolittle (1982) hydrophobicity plot and applied the SOSIU algorithm (Hirokawa et al., 1998) . The results indicated that ORF0 has a single TMD at its C-terminus but no N-terminal signal sequence (Fig. 1C ). Since these are the defining characteristics of TA proteins (Koshizuka et al., 2002) , the HSV-2 homolog of VZV ORF0 is a TA protein.
Expression of ORF0 proteins
To detect the ORF0 proteins, we generated rabbit antibodies against the N-terminal region of ORF0. On immunoblots, one of the resulting antisera specifically reacted with lysates from cells infected with either pOka or vOka ( Fig. 2A) . ORF0 was detected as a 17-kDa polypeptide in pOka-infected cells at 24 hpi and thereafter. In vOkainfected cells, the ORF0 was detected as a smeared band of 19-to 30-kDa polypeptides, beginning at 48 hpi.
Indirect immunofluorescence was used to determine the intracellular localization of ORF0 in VZV-infected cells (Fig. 2B) . pOka-and vOka-infected cells were fixed, respectively, at 48 and 72 hpi. In MRC-5 cells infected with either virus, the ORF0 immunoreactivity accumulated at the perinuclear region of the cytoplasm and at the plasma membrane. In MeWo cells infected with either pOka or vOka, the anti-ORF0 staining was marked at the plasma membrane and visible at the perinuclear region. In both cell lines, ORF0 partially colocalized with gB, a viral envelope glycoprotein (Fig. 2B ).
Expression of vOka ORF0 splice variants
To determine whether the differing C-termini of the vOka ORF0 variants led to a difference in their intracellular localizations, we constructed the corresponding ORF0 expression plasmids and examined their expression in transfected cells (Fig. 3) . The anti-ORF0 staining for pOka ORF0 (Fig. 3A, pORF0 ) was found predominantly at the plasma membrane as was the splice variant of vOka ORF0 with the alanine at aa 154 (Fig. 3A, vORF0A ) and vORF0V, with a valine at aa 154 (Fig. 3A,  vORF0V ). The vOka ORF0 unspliced variant (vORF0N) was mislocalized, in that it was distributed throughout the cytoplasm (Fig. 3A) .
To evaluate the contribution of the ORF0 C-terminus to each variant's band pattern on immunoblots, we used the lysates of transfected cells. pORF0 was detected as a 17-kDa polypeptide in these lysates (Fig. 3B , lane 2), as in the lysates of pOka-infected cells. Similarly, like the ORF0 of vOka-infected cells, vORF0A (Fig. 3B , lane 3) and vORF0V (Fig. 3B , lane 4) appeared as smeared bands. In contrast, vORF0N was detected as a sharp band of 20 kDa (Fig. 3B, lane 4) . Therefore, the C-termini of the splice variants of vOka ORF0 caused the smeared band pattern.
N-linked glycosylation of vOka ORF0
To determine the specific cause of the smearing on the immunoblots, cells transfected with ORF0 plasmids or infected with VZV were 1, 4, 7 ). Samples were separated by SDS-PAGE and analyzed by western blotting. treated with endoglycosidases (Fig. 4) . Although PNGase-F had no affect on the pORF0 band pattern (Fig. 4A , lane 5), both vORF0A (Fig. 4A , lane 8) and vORF0V (Fig. 4A , lane 11) migrated faster after the treatment. Endo-H did not change the band patterns of vORF0A or vORF0V (Fig. 4A, lane 9) . However, the vORF0N band was not altered by either PNGase-F or Endo-H treatment (Fig. 4A, lanes 13-15) . Likewise, in the lysates of VZV-infected cells, the bands for vOka ORF0 were smaller after PNGase-F treatment but not after Endo-H treatment (Fig. 4B, lanes 8 and 9) . Thus, the vOka ORF0 protein translated from either splice variant is a glycoprotein modified with complex N-linked oligosaccharides.
ORF0 is incorporated into virus particles
To determine whether the ORF0 protein is a component of virus particles, pOka, and vOka virus particles were purified on a CsCl gradient and analyzed by western blotting (Fig. 5) . The peak fraction that contained virus particles was determined by PCR (Fig. 5) . As shown in Fig. 5 , ORF0 proteins were detected in the peak fraction of both pOka and vOka. An envelope protein, gB, and a tegument protein, ORF49, which is the homologue of HSV UL11, were used as virus particle markers. In support of this finding, neither a non-structural viral protein, ORF16, which is the homologue of HSV UL42, nor a cellular protein, EEA1, was detected in the peak fraction. These results indicate that virus particles were purified successfully and that the ORF0 protein is a component of both pOka and vOka virus particles.
To determine the membrane orientation of the ORF0 proteins, purified VZV virus particles were treated with Proteinase K (ProK) in the presence or absence of detergent and then analyzed by western blotting (Fig. 6A) . Proteins presented on the outside of virus particles, such the envelope glycoprotein gB, were sensitive to ProK both in the presence and absence of detergent (Fig. 6A, lanes 3, 4, 7, 8 ). The pOka ORF0 was sensitive to ProK only in the presence of detergent (Fig. 6A,  lanes 3, 4) , indicating that the N-terminus of pOka ORF0 was protected from ProK by the envelope and faced the tegument. The smeared bands of vOka ORF0 were sensitive to ProK in the absence of detergent (Fig. 6A, lane 7) , and the vOka ORF0 band was shifted down to the molecular weight of pOka ORF0. The vOka ORF0 was also sensitive to ProK in the presence of detergent (Fig. 6A, lane 8) . These results indicate that the C-terminus of the vOka ORF0 is presented on the surface of virus particles, but the N-terminus of both vOka and pOka ORF0 faces the tegument (Fig. 6B) .
Construction of pOka and vOka recombinant viruses bearing each other's ORF0
To determine whether the C-terminus of the vOka ORF0 altered the growth of VZV, a recombinant pOka in which the native ORF0 was replaced with that of vOka (rpOka-vORF0) and a recombinant vOka bearing the pOka ORF0 (rvOka-pORF0) were constructed by single-base substitution, as described in the Materials and methods. The successful substitution of the ORF0 stop codon was verified by sequencing, southern blotting (data not shown), and western blotting (Fig. 7A ). There was no difference from wild-type VZV in the mean plaque size of either recombinant virus (Fig. 7B ) in MeWo cells, indicating that the mutant C-terminus of the vOka ORF0 does not affect VZV growth.
To generate an ORF0-deficient virus, we constructed a recombinant virus rpOka-ORF0ΔTMD, which lacked the TMD of ORF0. No ORF0 protein was detected in rpOka-ORF0ΔTMD-infected cell lysates (Fig. 8A, ORF0 ). The ORF1 protein, which is a neighboring gene product of ORF0, was detected in the rpOka-infected cell lysates (Fig. 8A, ORF1 ), indicating that the neighboring gene was expressed normally. Viral gB was used as the marker of infection (Fig. 8A, gB) . The amount of ORF0 RNA was decreased in the rpOka-ORF0ΔTMD-infected cells compared to the rpOka-infected cells (Fig. 8B) . The growth of the rpOka-ORF0ΔTMD virus was not impaired in the plaque-formation assay using MeWo cells (Fig. 8C) . Because the amount of ORF0 RNA was decreased in the rpOka-ORF0ΔTMD-infected cells by RT-PCR (Fig. 8B) , the amount of ORF0 cDNA was compared with ORF1 cDNA by real-time PCR analysis. The copy number of ORF1 cDNA was set at 100%, and the abundance of ORF0 cDNA compared to ORF1 cDNA in the rpOka-infected cells was 97%, but it was 18% in the rpOka-ORF0ΔTMD-infected cells.
Discussion
The point mutation at the stop codon of pOka ORF0 caused the molecular weight differences in the ORF0 protein variant expressed by vOka. Because of this point mutation, the amino acid sequence at the C-terminus of vOka ORF0 was increased by 26 amino acids. When the stop codon was mutated in recombinant viruses, the molecular weight of the resulting ORF0 protein was changed to that of the vOka forms. These results indicate that the mutated C-terminal region of vOka ORF0 is responsible for its difference in molecular weight from pOka ORF0.
The N-terminus of the ORF0 protein was protected from ProK treatment, indicating that the N-terminus of the transmembrane domain faces the inside of the virus particle. Given the mechanisms of herpesvirus envelopment (Mettenleiter, 2002) , the N-terminus of ORF0 must face the cytoplasm in infected cells and the inside of virus particles in virions. The C-terminus of vOka ORF0 was presented on the surface of virus particles, and it appears to be N-glycosylated at its C-terminus. The pOka and vOka ORF0 have two putative Nglycosylation sites at amino acid positions 65 to 67 and 126 to 128. Although the pOka ORF0 possesses a putative N-glycosylation site at its C-terminus, it was not glycosylated, indicating that its C-terminus was inaccessible for glycosylation.
Given that the pOka and vOka ORF0s share their N-terminal and transmembrane sequences and that the N-terminus of both ORF0 proteins faces the cytoplasm of infected cells and the tegument of virus particles, the pOka and vOka ORF0s may interact with the same proteins and have similar N-terminally mediated functions. However, because of their different C-terminal sequences, their C-terminally mediated functions probably differ.
To date, the function of ORF0 remains unknown. The HSV-2 homolog of ORF0, UL56, which is mainly located at the perinuclear region of the cytoplasm (Koshizuka et al., 2002) , associates with a ubiquitin E3 ligase, Nedd4, through the PY motif of UL56 (Ushijima et al., 2008) . Because ORF0 also has a PY motif, it may also associate with Nedd4 family proteins. However, the intracellular localization of ORF0 differs from that of HSV-2 UL56, and therefore, ORF0 may possess one or more unique functions. In our experiments, viruses bearing the ORF0 stop codon mutants grew just as well as the wild-type virus, suggesting that the ORF0 mutation may not be related to the attenuation of vOka or that multiple point mutations of the VZV genome, including those in ORF0, may be necessary for the attenuation.
Similarly, even the complete removal of the ORF0 protein did not affect virus growth in our hands. A recombinant virus that lacked the TMD of ORF0 grew normally in MeWo cells, even though we confirmed that ORF0 was not expressed in them. This finding contradicts that of Zhang and colleagues, who reported that virus lacking the ORF0 gene showed severely retarded growth in vitro and in vivo (Zhang et al., 2007) . However, in their study, Zhang et al. (2007) deleted the entire ORF0 sequence, whereas we removed only the TMD. Therefore, the discrepancy between our reports may be explained if the growth of the virus was affected by the deletion of the additional sequences rather than by the loss of ORF0 expression. The nucleotide sequences in the vicinity of the ORF0 gene may be important for DNA cleavage and/or packaging of the VZV genome because the ORF0 gene is located at the genomic terminus. Alternatively, the C-terminal region of ORF0 may not affect the viral growth.
Although weak RNA expression of the TMD-deleted ORF0 was detected by RT-PCR, the protein was not detectable by western blotting. The C-terminal TMD-deleted ORF0 protein should be detectable by the anti-ORF0 serum because this mono-specific serum was raised against the N-terminal region (amino acid positions 1-99) of the ORF0 protein. Therefore, this mutant ORF0 protein may not be expressed or may be expressed at an undetectable level in the recombinant virus-infected cells. Alternatively, the truncated ORF0 may be less stable than the wild-type protein, thus resulting in our inability to detect the protein.
A difference in the cellular localization patterns between the ORF0s of pOka and vOka might have suggested differing functions for these proteins. However, the ORF0 proteins of both pOka and vOka accumulated in the perinuclear region of the cytoplasm in infected MRC5 and MeWo cells, and both ORF0s partially colocalized with gB in infected MRC5 cells. Both ORF0s were located at the cell rim of infected MeWo cells, indicating that they were localized to the plasma membrane, like the ORF1 protein . Thus, the localization patterns of the pOka and vOka ORF0 proteins did not differ substantially, and no clues to functional differences could be obtained from these data.
However, one way the function of the vOka ORF0 might be altered is through the N-linked glycosylation of its C-terminus, which we discovered because the bands of vOka ORF0 were smeared on immunoblots of infected and transfected cells. This novel modification might, in particular, affect vOka cell tropism. In the case of measles virus, the vaccine strain uses both SLAM and CD46 as receptors, whereas most wild-type strains use only SLAM (Dorig et al., 1993; Erlenhofer et al., 2002; Tatsuo et al., 2000) . Point mutations in the hemagglutinin protein of the vaccine strain account for the measles virus's use of CD46 (Tahara et al., 2007) . The C-terminus of vOka ORF0 may affect the attachment of vOka virus particles to target cells, by altering its interactions with cellular molecules. If this scenario is correct, antibodies raised against the C-terminus of vOka ORF0 may be responsible for the neutralization of the virus. In addition, some other post-translational modification(s) may contribute to changes in vOka ORF0 function. Even after the N-glycosylation was removed by digestion with PNGase-F, the band pattern of vOka ORF0 was still smeared. This issue will be addressed in future studies.
Materials and methods
Cells and viruses
MRC-5 cells were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). Human melanoma cells (MeWo) and 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. The VZV strains, pOka and vOka, were propagated in MRC-5 cells or MeWo cells. The preparation of cell-free viruses and the purification of virus particles from the infected MeWo cells were described previously . Purified virus particles were analyzed by electron microscopy with negative staining, as described previously (Sadaoka et al., 2007) .
Plasmids
The Escherichia coli expression plasmid pGEX-ORF0 was constructed by amplifying the domains encoding ORF0 codons 1 to 99 by PCR from the pOka genome and cloning the resulting DNA fragment into pGEX-4T-1 (GE Healthcare Biosciences, Piscataway, NJ) in frame with glutathione-S-transferase (GST). In pGEX-ORF0, the initiation methionine of ORF0 was altered to alanine. Total RNAs were extracted from pOka-or vOka-infected MeWo cells by TRIzol reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's manual. The cDNA was prepared by reverse transcription (RT) with oligo(dT) using the Superscript III kit (Invitrogen). The DNA fragment of full-length ORF0 was amplified from pOka cDNA by PCR with primers ORF0-f1 (GGGGGCGGCCGCCATGGCGACCGTGCACTAC; NotI site is underlined) and ORF0-r3 (GGGGCTCGAGTCATGTAGTTGAGTTGGG; XhoI site is underlined). The DNA fragment was cloned into pCAGGS-MCS (Niwa et al., 1991) to generate pCAGGS-pORF0.
The vOka ORF0 was amplified from vOka cDNA by PCR with primers ORF0-f1 and ORF0-r4 (GGGGCTCGAGTCAGCATACAGAGCT-TATGCAG; XhoI site is underlined), cloned into pCR2.1-TOPO (Invitrogen), and sequenced. Spliced vOka ORF0 cDNA was amplified by PCR with ORF0-f1 and ORF0-rvA (GGGCTCGAGTTATTCCACTGGTT-GATGTCC; XhoI site is underlined) and cloned into pCAGGS-MCS to generate pCAGGS-vORF0A. The splicing donor site of unspliced vOka ORF0 was substituted by PCR with primers splice-mutF (CCGGAAGGGGAAGGCATTTATTCTCGCTTG) and splice-mutR (CAAGCGAGAATAAATGCCTTCCCCTTCCGG) to generate a splicingincompetent mutant, pCAGGS-vORF0N.
Antibodies
The GST-ORF0 (amino acid positions 1-99) fusion protein was purified with glutathione sepharose beads (GE Healthcare Bioscience) and used as an antigen to generate rabbit anti-ORF0 mono-specific antibodies. The purification of anti-ORF0 was performed as described previously . The anti-glycoprotein B (gB), anti-ORF16, and anti-ORF49 rabbit antibodies were described previously (Sadaoka et al., 2007) . The anti-gB monoclonal antibody was described previously (Okuno et al., 1983) . The anti-EEA1 (clone 14; BD Biosciences Pharmingen) monoclonal antibody was purchased.
Immunofluorescence assay MRC-5 or MeWo cells were grown on coverslips and subjected to an immunofluorescence assay as described previously .
Transfection
MeWo cells were transfected with the indicated plasmids by Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. 293T cells were transfected with the indicated plasmids by the calcium phosphate method. Ten micrograms of plasmid DNA was combined with 50 μl of 2.5 M CaCl 2 and 440 μl of sterile water. The calcium-DNA solution was mixed with 2× HEPES-buffered saline (140 mM NaCl, 1.5 mM Na 2 HPO 4 , 50 mM HEPES, pH 7.1). After incubation at RT for 30 min, the calcium phosphate-DNA suspension was transferred to the 293T cells. After another incubation, the medium was changed, and the 293T cells were harvested at 72 h post transfection.
Purification of virus particles
VZV virions were purified as described previously (Sadaoka et al., 2007) . After the second Histodenz gradient purification, the virus particle-containing fraction was diluted with PBS and pelleted by centrifugation at 27,000 rpm for 2 h at 4°C with a P40ST rotor (Hitachi). The pellet was suspended in PBS and layered onto a continuous 10-40% CsCl gradient, followed by centrifugation at 20,000 rpm for 48 h at 4°C with a P40ST rotor (Hitachi). Fractions were collected from the bottom and analyzed by western blotting. Viral DNA was purified from fractions and analyzed by PCR using the primer pair ORF0-f1 and ORF0-r2 (GTCGACCTCACGGTACACAGCATTTGCG).
Protease assay
The protease assays were performed essentially as described previously (Koshizuka et al., 2002) . Protease inhibitor cocktail (Sigma) was added to purified virus particles to prevent unexpected proteolysis. The purified virus particles were treated with ProK at a final concentration of 500 μg/ml in the presence or absence of 1% Triton X-100. After an incubation at 37°C for 30 min, 2 mM PMSF was added to the samples to terminate the ProK reaction, and the samples were incubated on ice for 5 min. The samples were subjected to SDS-PAGE without boiling and analyzed by western blotting.
BAC mutagenesis
The recombinant pOka virus (rpOka) was constructed as previously reported (Nagaike et al., 2004; Yoshii et al., 2007) . In brief, rpOka was reconstituted by transfecting MRC-5 cells with the pOka-BAC genome (pOka-BAC) (Nagaike et al., 2004; Yoshii et al., 2007) . To remove the BAC sequence, the MRC-5 cells were first infected with a recombinant adenovirus, AxCANCre, which expresses the Cre recombinase (kindly provided by Dr. Y. Kawaguchi). The cells were then super-infected with the recombinant virus and cultured until plaques without GFP appeared (Kanegae et al., 1995; Tanaka et al., 2003) .
To generate recombinant virus with the C-terminus TMD of ORF0 deleted (rpOkaORF0ΔTMD), nucleotide positions 457-589 of the pOka genome were replaced with a kanamycin resistance (Km r ) gene.
The DNA fragments containing the Km r gene were amplified with primers dORF0TMDfw407-456 (5′-ATGATGGAATCCACAGACTT-CAGCTGGCTTTTCTAAGAATTCGCAAATGCGAAGTTCCTATTCTCTA-GAAAGTATAGGAACTTCAGCAAGCGAACCGGAATTGC-3′) and dORF0TMDrv590-541 (5′-TAAATACCTTCCCCTTCCGGACAGTAGTTT-CATGTAGTTGAGTTGGGAGGGAAGTTCCTATACTTTCTAGAGAATAG-GAACTTCCTTTTTCAATTCAGAAGAACTC-3′). The DNA fragments were introduced by electroporation into E. coli DH10B harboring the pOka-BAC genome and pGETrec, which was a kind gift from Dr. P. A. Ioannou (Narayanan et al., 1999) . To generate recombinant viruses in which the ORF0 of vOka was replaced by the one for pOka and vice-versa, the stop codon of pOka ORF0 (at nucleotide position 560 of the VZV genome) was replaced with the codon for arginine, and the arginine codon of vOka ORF0 was replaced with the stop codon. These changes were performed using a two-step Red-mediated mutagenesis procedure (Tischer et al., 2006) in E. coli GS1783, essentially as described by Jarosinski et al. (2007) . E. coli GS1783 harboring the pOka-BAC or vOka-BAC genome was used. The primer pairs for the amplification were as follows: ORF0pv1 (5′-GTTGCCGTTTTTCCCGAGGAACCTCCCAACTCAACTACACGAAAC-TACTGTCCGGAAGGGAGGATGACGACGATAAGTAGGG-3′) and ORF0pv2 (5′-AAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCGTGTAGTT-GAGTTGGGAGGTCAACCAATTAACCAATTCTGATTAG-3′) or ORF0vp1 (5′-GTTGCCGTTTTTCCCGAGGAACCTCCCAACTCAACTACATGAAAC-TACTGTCCGGAAGGGAGGATGACGACGATAAGTAGGG-3′) and ORF0vp2 (5′-AAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCATGTAGTT-GAGTTGGGAGGTCAACCAATTAACCAATTCTGATTAG-3′). The substitution site is underlined. The successful recombination was confirmed by PCR and southern blotting. MeWo cells were transfected with the recombinant virus genomes by using the Lipofectamine 2000 reagent.
Growth analysis of recombinant viruses
MeWo cells were infected with cell-free rpOka, rpOka-vORF0, rvOka, rvOka-pORF0, or rpOkaORF0ΔTMD viruses and incubated at 37°C. The medium was replaced every 2 days, and the cells were stained with 1% crystal violet/70% ethanol for analysis .
RT-PCR and real-time PCR
Total RNA was isolated from the recombinant virus-infected MeWo cells using TRIzol (Invitrogen), and its concentration and purity were determined by spectrophotometry. The RNA integrity was verified by electrophoresis on 1.2% denaturing formaldehyde gels. One microgram of total RNA was transcribed using Superscript III reverse transcriptase (Invitrogen). An equal amount of cDNA (1/10 of the reaction) was used in each PCR. PCR was performed using GoTaq Green Master Mix (Promega). A primer pair for the human elongation factor gene was used as the control (EF-F: GCTCCAGCATGTTGTCACCATTC; EF-R: GGTGAATTT-GAAGCTGGTATCTC). The ORF0 cDNA was detected using primers ORF0-f1 and ORF0-reverse (GTGCCATTCTCCACGTGAGG).
SYBR Green PCRs were performed in an Applied Biosystems 7300 real-time PCR system (Applied Biosystems, Foster City, CA) with specific primers for ORF0 (ORF0-f1 and ORF0-reverse:GTGCCATTCTC-CACGTGAGG) and ORF1 (ORF1-1f: GAATTCGCGTCCAGGGTATCG-GAGTA and ORF1-2r: CTCGAGTTAGCATAACCTGTCCATTTGCAT), according to the manufacturer's manual. The thermal profile for all SYBR Green PCRs was 95°C for 10 min, followed by 40 cycles of 95°C for 10 s, 58°C for 20 s, and 72°C for 30 s. At the end of each SYBR Green PCR run, data analysis was performed by the SDS program version 1.4 (Sequence Detection Software; Applied Biosystems). Each sample was analyzed in duplicate.
